Sintilimab-induced immune-related hepatitis

王春晖,李倩雯,吴薇,李晓宇,吕迁洲

DOI: https://doi.org/10.3760/cma.j.cn114015-20190926-00787

2020-01-01

Abstract:A 49-year-old male patient was treated with first-line and second-line chemotherapy regimens successively for 7 months because of Hodgkin′s lymphoma. However, the tumor failed to be well controlled. His treatment was changed to intravenous infusion of sintilimab 200 mg once every 21 days. His liver function was normal before treatment. After the second administration of sintilimab (on day 42 after the first medication), the patient developed chest distress, abdominal distension, poor appetite, and etc. Reexamination of liver function showed alanine aminotransferase (ALT) 1 590 U/L, aspartate aminotransferase (AST) 3 678 U/L, alkaline phosphatase (ALP) 468 U/L, gamma-glutamyl transferase (γ-GT) 399 U/L, total bilirubin (TBil) 50.1 μmol/L, and direct bilirubin (DBil) 26.8 μmol/L. Sintilimab was discontinued, but the patient′s jaundice was deteriorated. Intravenous infusion of methylprednisolone 150 mg once daily was given for 3 days, but the bilirubin reached the peak (TBil 152.6 μmol/L, DBil 109.2 μmol/L). Oral mycophenolate mofetil 0.5 g twice daily was added, the patient′s symptoms were gradually improved, and his liver function gradually recovered. After 6 days of combination use of methylprednisolone and mycophenolate mofetil, the laboratory tests showed ALT 63 U/L, AST 78 U/L, TBil 25.2 μmol/L, and DBil 12.9 μmol/L. Twenty-two dags later, his liver function returned to normal.